Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Riconpharma LLC is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution is focused, involving 1 distinct examiner, WEBB, WALTER E. As the busiest examiner for the company, WEBB, WALTER E is responsible for the entirety of the company's active office actions. This focus means that the company's immediate patent strategy is dependent on this one examiner's evaluation.
The involvement of 1 distinct art unit for the 1 pending office action indicates a specific technical focus for the company's current patent applications. With 1 pending office action representing the total volume of the portfolio's active prosecution, the company's immediate IP goals are tied to a single examiner's review. This focus in the Biotechnology & Pharmaceuticals sector allows for a direct prosecution strategy, though it lacks the diversification found in larger portfolios.
By focusing resources on the 1 pending office action with 1 distinct examiner, the company can maintain oversight on its intellectual property development. The outcome of this matter is the primary factor in the company's immediate success in the US patent system. This concentrated profile in 1 distinct art unit suggests a specific technological niche for the company's current filings. WEBB, WALTER E handles the busiest_examiner_pending count of 1 for the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEBB, WALTER E | 1 | 46.3% | +18.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18991888 | AN INJECTABLE AQUEOUS-BASED LEUCOVORIN FORMULATION AND PREPARATION METHOD THEREOF | WEBB, WALTER E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18991888 | AN INJECTABLE AQUEOUS-BASED LEUCOVORIN FORMULATION AND PREPARATION METHOD THEREOF | WEBB, WALTER E | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18991888 | AN INJECTABLE AQUEOUS-BASED LEUCOVORIN FORMULATION AND PREPARATION METHOD THEREOF | WEBB, WALTER E | 1612 | §103§112 | Non-Final OA | — | Pending | Dec 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRiconpharma LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Walter E Webb has the most, with 1 of Riconpharma LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.